Financial Tables | Printer Friendly Version 

Highlights:

  • Revenue of $1.72 billion represents 6.8% reported growth year-over-year; and up 9.5% on a core(1) basis.
  • GAAP net income of $302 million with earnings per share (EPS) of $1.02, up 12% from the second quarter of 2022.
  • Non-GAAP(2) net income of $377 million with EPS of $1.27, up 12% from the second quarter of 2022.
  • Full-year revenue is now expected to be in the range of $6.93 billion to $7.03 billion, representing reported growth of 1.2% to 2.7% and core(1) growth of 3.0% to 4.5%. Fiscal year 2023 non-GAAP(3) EPS is now estimated to be in the range of $5.60 to $5.65.
  • Third-quarter revenue is expected to be in the range of $1.640 billion to $1.675 billion with non-GAAP(3) EPS of $1.36 to $1.38. 

Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.72 billion for the second quarter ended April 30, 2023, an increase of 6.8% compared to the second quarter of 2022 and up 9.5% on a core(1) basis.

Second-quarter GAAP net income was $302 million, or $1.02 per share. This compares with $274 million, or 91 cents per share, in the second quarter of fiscal year 2022. Non-GAAP(2) net income was $377 million, or $1.27 per share during the quarter, compared with $340 million or $1.13 per share during the second quarter a year ago.

“In an increasingly challenging market environment, the Agilent team delivered solid results in the second quarter,” said Agilent President and CEO Mike McMullen. “Revenues of $1.72 billion are up 9.5 percent core(1) with growth across all end markets and regions. Our results are driven by an innovative and broad portfolio, a differentiated customer experience, and outstanding execution.”

Financial Highlights

Life Sciences and Applied Markets Group
Agilent’s Life Sciences and Applied Markets Group (LSAG) reported second-quarter revenue of $968 million, a year-over-year increase of 8% (up 10% on a core(1) basis). LSAG’s operating margin for the quarter was 27.3%.

Agilent CrossLab Group
The Agilent CrossLab Group (ACG) reported second-quarter revenue of $387 million, a year-over-year increase of 10% (up 13% on a core(1) basis). ACG’s operating margin for the quarter was 26.6%. 

Diagnostics and Genomics Group
The Diagnostics and Genomics Group (DGG) reported second-quarter revenue of $362 million, a year-over-year increase of 1% (up 3% on a core(1) basis). DGG’s operating margin for the quarter was 20.2%.

Full Year and Third-Quarter Outlook

Reflecting increased market uncertainties, full-year revenue is now expected to be in the range of $6.93 billion to $7.03 billion, representing reported growth of 1.2% to 2.7% and core(1) growth of 3.0% to 4.5%.  Fiscal year 2023 non-GAAP(3) EPS guidance is now estimated to be in the range of $5.60 to $5.65.

The outlook for third-quarter revenue is expected to be in a range of $1.640 billion to $1.675 billion. Third-quarter non-GAAP(3) earnings guidance is expected to be in the range of $1.36 to $1.38 per share.

The outlook is based on forecasted currency exchange rates.

Conference Call

Agilent’s management will present additional details regarding the company’s second-quarter 2023 financial results on a conference call with investors today at 1:30 p.m. PDT. This event will be broadcast live online in listen-only mode. To listen to the webcast, select the “Q2 2023 Agilent Technologies Inc. Earnings Conference Call” link on the . The webcast will remain on the company site for 90 days.